Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Minoru Tanabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4875-1471; OpenAlex author ID A5036510227, A5054898689, A5103204983. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
71
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 23

  1. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  4. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-1095↗
  5. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  6. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Co-author DOI 10.1002/cam4.7459↗
  7. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  8. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Co-author DOI 10.1111/cas.15615↗
  9. Prognostic Value of Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer Stratified by Cytologic Status. Co-author DOI 10.21873/cdp.10221↗
  10. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Last author DOI 10.3892/ijo.2023.5499↗
  11. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer. Co-author DOI 10.1038/s41598-022-14297-5↗
  12. Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location. Co-author DOI 10.1245/s10434-021-11108-5↗
  13. Extraordinary first jejunal arterial variation associated with annular pancreas undergoing pancreaticoduodenectomy for pancreatic cancer: a case report. Last author DOI 10.1007/s00276-020-02671-9↗
  14. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Last author DOI 10.1038/s41598-021-89530-8↗
  15. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. Last author DOI 10.1371/journal.pone.0249885↗
  16. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0252917↗
  17. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting fo… Last author DOI 10.1186/s40792-020-01082-7↗
  18. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Co-author DOI 10.1002/ijc.32072↗
  19. Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line. Co-author DOI 10.1111/cas.13783↗
  20. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jhbp.366↗
  21. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis. Last author DOI 10.1371/journal.pone.0146564↗
  22. Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2013.11.017↗
  23. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.53↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shinji Tanaka · 10 shared papers, 2016–2025 · strength 1.22
  2. Hiroaki Ono · 8 shared papers, 2019–2025 · strength 1.05
  3. Daisuke Ban · 9 shared papers, 2016–2025 · strength 0.99
  4. Kosuke Ogawa · 7 shared papers, 2019–2023 · strength 0.86
  5. Shuichi Watanabe · 6 shared papers, 2019–2023 · strength 0.73
  6. Toshiro Ogura · 5 shared papers, 2019–2023 · strength 0.67
  7. Tomotaka Kato · 3 shared papers, 2021–2023 · strength 0.40
  8. Yoshiki Murase · 3 shared papers, 2020–2023 · strength 0.37
  9. Amane Takahashi · 2 shared papers, 2022–2023 · strength 0.35
  10. Ryoichi Miyamoto · 2 shared papers, 2022–2023 · strength 0.35
  11. Hiroyuki Ishida · 2 shared papers, 2022–2023 · strength 0.35
  12. Yoshiyuki Kawashima · 2 shared papers, 2022–2023 · strength 0.35
  13. Aya Maekawa · 3 shared papers, 2020–2023 · strength 0.35
  14. Daisuke Asano · 2 shared papers, 2023 · strength 0.31
  15. Ayano Kabashima · 2 shared papers, 2022–2023 · strength 0.31
  16. Takeshi Ishii · 2 shared papers, 2022–2023 · strength 0.31
  17. Toshitaka Sugawara · 2 shared papers, 2021–2023 · strength 0.25
  18. Minoru Kitago · 2 shared papers, 2014–2024 · strength 0.22
  19. Kentaro Umemura · 1 shared paper, 2025 · strength 0.19
  20. Yosuke Igarashi · 1 shared paper, 2025 · strength 0.19
  21. Yoshiaki Tanji · 1 shared paper, 2025 · strength 0.19
  22. Yuji Soejima · 1 shared paper, 2025 · strength 0.19
  23. Atsushi Oba · 2 shared papers, 2016–2023 · strength 0.18
  24. Koichi Aiura · 1 shared paper, 2024 · strength 0.18
  25. Yuko Kitagawa · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.